Get In Touch

Demand for RNA-based COVID-19 Vaccines Creates Revenue Opportunities for Contact Manufacturers

Epidemiological studies indicate that patients with asthma are not at an increased risk of severe COVID-19. Although the severity of coronavirus in patients with asthma is dependent on many factors, currently, there is scarce information on the risks associated with COVID-19 in patients with severe asthma that consume biologics. Nevertheless, companies in the biologics contract manufacturing market are tapping revenue opportunities in vaccine production in order to reduce incidences of the novel infection.

Companies in the global biologics contract manufacturing market are shifting their focus to RNA-based COVID-19 vaccines. In order to meet the demands of the patients, an increasing number of pharmaceutical and biotech companies are entering into mergers & agreements with contract manufacturers to develop COVID-19 vaccines.

biologics contract manufacturing market infographic

Request a sample to get extensive insights into the Biologics Contract Manufacturing Market

Process Intensification Holds Promising Potentials to Accelerate Business of Life-altering Therapeutics

In order to leverage value-grab opportunities in biologic therapies, it has become imperative to eliminate manufacturing bottlenecks with the help of process intensification (PI). Sartorius AG - an international pharmaceutical and laboratory equipment supplier, covering the segments of bioprocess solutions and lab products & services, is offering solutions for process intensification to accelerate the business of life-altering therapeutics during the ongoing pandemic.

Biologics complexities and long production cycles are fueling the need for PI. Such trends are contributing to the expansion of the biologics contract manufacturing market. PI is helping contract manufacturers to meet key regulatory deadlines, which is crucial for staying ahead in competition. This trend is essential in the manufacturing of biosimilars that need to be produced in several successive batches in a compressed timeline.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Commercialization of Ublituximab for Blood Cancer Treatment

The biologics contract manufacturing market is expected surpass US$ 47.3 Bn by 2031. Monoclonal antibodies are emerging as an important therapeutic approach for blood cancer treatment. TG Therapeutics, Inc. - a clinical-stage biopharmaceutical company, has announced to expand its contract manufacturing deal with Samsung Biologics - a South Korean biotechnology company, to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.

Companies in the biologics contract manufacturing market are entering into multiple collaborations to increase the availability of ublituximab and enable its commercialization. Companies are re-evaluating their supply needs and securing long-term capacity to meet the global demand for ublituximab.

Glass Containment Solutions and Drug Delivery Devices Ideal for Next-gen Biologics

The biologics contract manufacturing market is projected to clock a CAGR of 12.2% during the forecast period. Stevanato Group - a specialist in world-class systems, processes, and services for pharmaceutical & healthcare industry, is providing novel glass drug containment solutions and drug delivery devices ideal for next-gen drugs.

With the help of state-of-the-art analytical services, reliable technology, and manufacturing equipment, companies in the biologics contract manufacturing market are able to capitalize on incremental opportunities. Biotech drugs such as recombinant proteins and monoclonal antibodies are fueling the demand for glass drug containment solutions and drug delivery devices. The high prevalence of rheumatoid arthritis and osteoporosis is triggering the demand for biologics.

biologics contract manufacturing market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Biologics Contract Manufacturing Market

Analysts’ Viewpoint

Due to very low margin for error in the production of life-altering therapeutics for COVID-19 treatment and prevention, companies in the biologics contract manufacturing market should adopt process intensification to avoid production failure. Companies are setting their collaboration wheels in motion to enable long-standing R&D activities involving monoclonal antibodies for blood cancer treatment. Since biologics are challenging to stabilize and administrate, especially in a syringe or a drug delivery device owing to their viscosity, complexity, and sensitivity, companies are using glass drug containment solutions to commercialize biologics. These solutions are necessary since biologics undergo stringent regulatory assessments as compared to generic drugs.

Biologics Contract Manufacturing Market: Overview

  • According to Transparency Market Research’s latest market report on the global biologics contract manufacturing market for the historical period of 2017–2019 and forecast period from 2021 to 2031, growth of the biopharmaceutical industry and promising drug pipeline are projected to drive the global biologics contract manufacturing market during the forecast period
  • According to the report, the global biologics contract manufacturing market was valued at US$ 13.3 Bn in 2020 and is anticipated to expand at a CAGR of 12.2% from 2021 to 2031

Growth of Biopharmaceutical Industry and Promising Drug Pipeline: Key Drivers

  • Increase in biopharmaceutical sales and pipeline drugs drive the need of biologics clinical development and manufacturing services, from pre-clinical services to commercial manufacturing
  • Over 3,500 recombinant proteins and antibodies are in pre-clinical and clinical trials, including treatments that have been approved
  • An increasing number of pipeline molecules are being developed by small and virtual biotech companies. These do not normally have the in-house manufacturing capacity and expertise to bring their candidates to market, and therefore, have a higher propensity to outsource. Presently, these emerging biopharma companies constitute around 80% of the development pipeline.

Increase in Investment in Research & Development

  • Demand for the development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market are investing in research & development programs in order to develop new drugs.
  • Recent intensive researches in novel and combination therapies have established the efficacy of biologics for treating a range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration, and hematological malignancies
  • According to CBO, R&D costs have increased by about 8.5% per year in the last decade
  • The 2020–2021 coronavirus pandemic has spurred the development of vaccines to halt the spread of COVID-19. In addition to R&D spending by the private sector, the federal government has provided support to the private sector to develop vaccines to address the pandemic.
  • Hence, increase in investment in research & development programs is likely to boost the growth of the market during the forecast period

High Cost of Treatment to Restrain Biologics Contract Manufacturing Market

  • Biologics are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other autoimmune diseases. These are highly targeted, efficacious, and have been widely adopted in the treatment of several diseases.
  • According to data from the IQVIA Institute, in 2017, biologic drugs represented 2% of all the U.S. prescriptions, but 37% of net drug spending
  • Traditional medicines (small molecules) have relatively simple chemical structures. For instance, Lipitor (atorvastatin), a best-selling cholesterol-lowering drug, comprises 76 atoms and is quite cheap to manufacture. However, biologic drugs (or large molecules) such as monoclonal antibodies are complex proteins, manufactured in living cells, which is a costlier process. Humira (adalimumab), the nation’s top drug in terms of revenue, contains 20,067 atoms.
  • Therefore, high cost of biologic drugs is likely to restrain the global market during the forecast period

Biologics Contract Manufacturing Market: Competition Landscape

  • This report profiles major players in the global biologics contract manufacturing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The biologics contract manufacturing market is fragmented, with the presence of large number of global players and many small players in regional markets
  • Prominent players operating in the global biologics contract manufacturing market include
    • Lonza Group
    • Samsung Biologics Co., Ltd.
    • Patheon by Thermo Fisher Scientific, Inc.
    • Cambrex Corporation
    • Siegfried Holding AG
    • Fujifilm Holding Corporation
    • AbbVie, Inc.
    • Boehringer Ingelheim
    • Recipharm Pharmaceuticals.
    • WuXi Biologics
    • Catalent, Inc.

Biologics Contract Manufacturing Market: Key Developments

  • In August 2021, Catalent, Inc. acquired RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.
  • In May 2021, Charles River Laboratories signed a definitive agreement to acquire U.S.-based gene therapy CDMO, Vigene Biosciences, for US$ 292.5 Mn
  • In March 2021, WuXi Biologics closed the acquisition of biologics drug substance and product facilities (MFG20/DP9/DP10) from Pfizer China located in Hangzhou, with 2 x 2,000L single-use bioreactors that can be expanded to 4 x 2,000L. The company also acquired CMAB, a biologics contract development and manufacturing organization (CDMO) with operations in Suzhou, China.
  • In December 2020, WuXi Biologics signed an agreement with Bayer to take over the operations and assets of a drug substance facility (MFG19) located in Wuppertal, Germany that will include 3 x 1,000L perfusion and 6 x 2,000L fed-batch capacity with independent downstream suites.
  • In August 2020, Samsung Biologics announced an investment of US$ 1.7 Bn for a new biomanufacturing plant, the company’s fourth, in Incheon, South Korea, and for a second bio complex
  • The report on the global biologics contract manufacturing market discusses individual strategies, followed by company profiles of biologics contract manufacturing providers. The competition landscape section has been included in the global biologics contract manufacturing market report to provide readers with a dashboard view of key market players operating in the global biologics contract manufacturing market.

Biologics Contract Manufacturing Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 13.3 Bn

Market Forecast Value in 2031

US$ 47.3 Bn

Growth Rate (CAGR)

12.2%

Forecast Period

2021–2031

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, supply chain analysis, and parent industry overview.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Vaccines
    • Molecular Therapy
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Customization Scope

Available upon request

Pricing

Available upon request

Biologics Contract Manufacturing Market – Scope of Report

TMR’s report on the global biologics contract manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global biologics contract manufacturing market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biologics contract manufacturing market from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biologics contract manufacturing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biologics contract manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global biologics contract manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biologics contract manufacturing market.

The report delves into the competition landscape of the global biologics contract manufacturing market. Key players operating in the global biologics contract manufacturing market have been identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biologics contract manufacturing market profiled in this report.

Key Questions Answered in Biologics Contract Manufacturing Market Report

  • What is the sales/revenue generated by biologics contract manufacturing across all regions during the forecast period?
  • What are the opportunities in the global biologics contract manufacturing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which type segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Biologics Contract Manufacturing Market – Research Objectives and Research Approach

The comprehensive report on the global biologics contract manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global biologics contract manufacturing market in terms of type and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biologics contract manufacturing market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Biologics Contract Manufacturing Market – Segmentation

TMR’s study on the global biologics contract manufacturing market includes information divided into five segments: type and region. Changing industry trends and other market dynamics associated with these segments of the global biologics contract manufacturing market are discussed in detail.

Type
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Molecular Therapy
  • Others (RNAi, Antisense RNA, etc.)
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biologics Contract Manufacturing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Biologics Contract Manufacturing: Overview

    5.2. Trends in Biopharma Contract Manufacturing

    5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value & Volume Forecast, by Type, 2017–2031

        6.3.1. Monoclonal Antibodies

        6.3.2. Recombinant Proteins

        6.3.3. Vaccines

        6.3.4. Molecular Therapy

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Type

7. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value & Volume Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Country/Region

8. North America Biologics Contract Manufacturing Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value & Volume Forecast, by Type, 2017–2031

        8.2.1. Monoclonal Antibodies

        8.2.2. Recombinant Proteins

        8.2.3. Vaccines

        8.2.4. Molecular Therapy

        8.2.5. Others

    8.3. Market Value & Volume Forecast, by Country, 2017–2031

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Type

        8.4.2. By Country

9. Europe Biologics Contract Manufacturing Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value & Volume Forecast, by Type, 2017–2031

        9.2.1. Monoclonal Antibodies

        9.2.2. Recombinant Proteins

        9.2.3. Vaccines

        9.2.4. Molecular Therapy

        9.2.5. Others

    9.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Spain

        9.3.5. Italy

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Type

        9.4.2. By Country/Sub-region

10. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value & Volume Forecast, by Type, 2017–2031

        10.2.1. Monoclonal Antibodies

        10.2.2. Recombinant Proteins

        10.2.3. Vaccines

        10.2.4. Molecular Therapy

        10.2.5. Others

    10.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031

        10.3.1. China

        10.3.2. Japan

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Type

        10.4.2. By Country/Sub-region

11. Latin America Biologics Contract Manufacturing Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value & Volume Forecast, by Type, 2017–2031

        11.2.1. Monoclonal Antibodies

        11.2.2. Recombinant Proteins

        11.2.3. Vaccines

        11.2.4. Molecular Therapy

        11.2.5. Others

    11.3. Market Value & Volume Forecast, by Country//Sub-region, 2017–2031

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Type

        11.4.2. By Country/Sub-region

12. Middle East & Africa Biologics Contract Manufacturing Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value & Volume Forecast, by Type, 2017–2031

        12.2.1. Monoclonal Antibodies

        12.2.2. Recombinant Proteins

        12.2.3. Vaccines

        12.2.4. Molecular Therapy

        12.2.5. Others

    12.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Type

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Company Profiles

        13.1.1. Lonza Group

            13.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.1.2. Product Portfolio

            13.1.1.3. SWOT Analysis

            13.1.1.4. Strategic Overview

        13.1.2. Samsung Biologics Co., Ltd.

            13.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.2.2. Product Portfolio

            13.1.2.3. SWOT Analysis

            13.1.2.4. Strategic Overview

        13.1.3. Patheon by Thermo Fisher Scientific, Inc.

            13.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.3.2. Product Portfolio

            13.1.3.2. SWOT Analysis

            13.1.3.3. Strategic Overview

        13.1.4. Cambrex Corporation

            13.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.4.2. Product Portfolio

            13.1.4.3. SWOT Analysis

            13.1.4.4. Strategic Overview

        13.1.5. Siegfried Holding AG

            13.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.5.2. Product Portfolio

            13.1.5.3. SWOT Analysis

            13.1.5.4. Strategic Overview

        13.1.6. Fujifilm Holding Corporation

            13.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.6.2. Product Portfolio

            13.1.6.3. SWOT Analysis

            13.1.6.4. Strategic Overview

        13.1.7. AbbVie, Inc.

            13.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.7.2. Product Portfolio

            13.1.7.3. SWOT Analysis

            13.1.7.4. Strategic Overview

        13.1.8. Boehringer Ingelheim

            13.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.8.2. Product Portfolio

            13.1.8.3. SWOT Analysis

            13.1.8.4. Strategic Overview

        13.1.9. Recipharm Pharmaceuticals

            13.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.9.2. Product Portfolio

            13.1.9.3. SWOT Analysis

            13.1.9.4. Strategic Overview

        13.1.10. WuXi Biologics

            13.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.10.2. Product Portfolio

            13.1.10.3. SWOT Analysis

            13.1.10.4. Strategic Overview

        13.1.11. Catalent, Inc.

            13.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.1.11.2. Product Portfolio

            13.1.11.3. SWOT Analysis

            13.1.11.4. Strategic Overview

List of Tables

Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017‒2031

Table 02: Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 03: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 04: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 06: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 11: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

List of Figures

Figure 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Biologics Contract Manufacturing Market Value Share, by Type, 2020

Figure 03: Biologics Contract Manufacturing Market Value Share, by Region, 2020

Figure 04: Global Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031

Figure 05: Global Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 06: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031

Figure 07: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017‒2031

Figure 08: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017‒2031

Figure 09: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017‒2031

Figure 10: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017–2031

Figure 11: Global Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031

Figure 12: Global Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021–2031

Figure 13: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 14: North America Biologics Contract Manufacturing Market Value Share Analysis, by Country, 2020 and 2031

Figure 15: North America Biologics Contract Manufacturing Market Attractiveness Analysis, by Country, 2021–2031 

Figure 16: North America Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 17: North America Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 18: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 19: Europe Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 20: Europe Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 21: Europe Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 22: Europe Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 23: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 24: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 25: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 26: Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 27: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 28: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: Latin America Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 30: Latin America Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 31: Latin America Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 32: Latin America Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 33: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 34: Middle East & Africa Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 35: Middle East & Africa Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021–2031

Figure 36: Middle East & Africa Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 37: Middle East & Africa Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Biologics Contract Manufacturing Market